Although present, some of them with high incidence, these markers are not useful for diagnostic, as they can be present in other types of cancer (e.g. EGFR mutations in non-small cell lung cancer) and, furthermore, therapeutic attempts with monoclonal antibodies targeting altered signaling pathways (EGFR singaling, VEGF singaling) failed to improve clinical outcome [15]. Here, VEGFA is linked to cancer.